Salesforce CEO, Bayer back biotech startup targeting 'good' gluten for celiac patients
With big plans to undercut celiac disease and disrupt food allergies, a biotech startup backed by high-profile investors and advisors raised $40 million to start clinical trials. Ukko Inc., with operations in Palo Alto and Tel Aviv, Israel, said its Series B round was led by drug maker Bayer AG's investment arm, Leaps by Bayer. It included cash from existing investors TIME Ventures — the investment fund of Salesforce.com Inc. (NYSE: CRM) founder and CEO Marc Benioff — as well as Khosla Ventures…
CONCLUSION: the validated recipes are of clinical and research interest, as they allow to confirm a peanut allergy and detect a wide range of tolerated threshold doses, which makes it possible to provide specific indications for each patient.PMID:34233225 | DOI:10.1016/j.anai.2021.06.024
Food has a significant role in our lives, yet, we practically have no idea what we eat. With the advent of industrial farming and the food processing industry, consumer control over food has been lost – and we lost track of substances. Food labels are far from providing enough information about what is actually in the package. Although labelling of allergens is mandatory in most countries, factual data is often hidden behind mysterious E-s and numbers. Various tech devices promise a solution. And a solution is indeed needed. About 7.5% of the global population is allergic to certain foods. Over 200,000 people requ...
Conclusion: Weight and eating are clear areas of risk for patients with orthostatic intolerance. It is essential that treatment team members thoroughly screen for eating disturbances and make recommendations that support regular and balanced eating habits.
World J Gastroenterol. 2021 Apr 7;27(13):1311-1320. doi: 10.3748/wjg.v27.i13.1311.ABSTRACTBACKGROUND: Non-responsive celiac disease (NRCD) is defined as the persistence of symptoms in individuals with celiac disease (CeD) despite being on a gluten-free diet (GFD). There is scant literature about NRCD in the pediatric population.AIM: To determine the incidence, clinical characteristics and underlying causes of NRCD in children.METHODS: Retrospective cohort study performed at Boston Children's Hospital (BCH). Children